|
Gastroenterology
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Korean J Intern Med. 2022;37(6):1167-1175. Published online May 27, 2022
Background/Aims: To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting.
Methods: A total of 273 patients who received LDV/SOF therapy between May 2016 and February 2021 were consecutively enrolle..
|
|
|
Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis
Young Woon Chang, Weon Jin Ko, Chi Hyuk Oh, Yoo Min Park, Shin Ju Oh, Jung Rock Moon, Jun-Hyung Cho, Jung-Wook Kim, Jae-Young Jang
Korean J Intern Med. 2019;34(5):1022-1029. Published online June 14, 2018
Background/Aims: The eradication rate of the first-line triple therapy (a proton pump inhibitor, clarithromycin, and amoxicillin) for Helicobacter pylori infection has gradually decreased in Korea. We evaluated whether clinical parameters, clarithromycin resistance, and CYP2C19 genotype can affect t..
|
|
|
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
Korean J Intern Med. 2019;34(4):794-801. Published online May 25, 2018
Background/Aims: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patient..
|
|
|
A third case of USA300 community-associated methicillin-resistant Staphylococcus aureus infection in Korea
Seungjin Lim, Doo Ryeon Chung, Jin Yang Baek, So Hyun Kim, Kyong Ran Peck, Nam-Yong Lee, Jae-Hoon Song
Korean J Intern Med. 2013;28(2):258-260. Published online February 27, 2013
|
|
|
Molecular Epidemiology of Hepatitis B Virus
Jia-Horng Kao
Korean J Intern Med. 2011;26(3):255-261. Published online September 13, 2011
Although safe and effective vaccines for hepatitis B virus (HBV) have been available for nearly three decades, this virus kills at least 600,000 people annually worldwide and remains the leading global cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Because the HBV reverse tr..
|
|
|
